论文部分内容阅读
美国贝塞斯达消息:继发现白细胞介素-2(IL-2)在体外对获得性免疫缺损综合征(AIDS)有效的结果后,现至少有三个临床试验正在美国进行。白细胞介素-2是由T淋巴细胞释放,引起细胞免疫的介导物。国立卫生研究院(NIH)和纽约的纪念斯隆-凯特林肿瘤中心发起了对IL-2的体内研究。在记者招待会上,参加此项研究的研究人员在讨论这些试验时仍不详细和含糊不清,并谨慎地强调区分在体外研究的好结果与在体内尚未明了的作用。
Bethesda, United States: Following the discovery in vitro of interleukin-2 (IL-2) that is effective for acquired immunodeficiency syndrome (AIDS), at least three clinical trials are currently ongoing in the United States. Interleukin-2 is a mediator released by T lymphocytes that causes cellular immunity. The National Institutes of Health (NIH) and Memorial Sloan-Kettering Cancer Center in New York initiated an in vivo study of IL-2. At the press conference, the researchers participating in the study were still not detailed or ambiguous when discussing the trials, and cautiously emphasized the distinction between the good results of the in-vitro studies and the unclear effects in the body.